EP2442649A1 - The use of metabotropic glutamate receptor potentiators for reducing nicotine dependence - Google Patents

The use of metabotropic glutamate receptor potentiators for reducing nicotine dependence

Info

Publication number
EP2442649A1
EP2442649A1 EP10790110A EP10790110A EP2442649A1 EP 2442649 A1 EP2442649 A1 EP 2442649A1 EP 10790110 A EP10790110 A EP 10790110A EP 10790110 A EP10790110 A EP 10790110A EP 2442649 A1 EP2442649 A1 EP 2442649A1
Authority
EP
European Patent Office
Prior art keywords
methyl
oxadiazol
piperazin
ylmethyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10790110A
Other languages
German (de)
French (fr)
Other versions
EP2442649A4 (en
Inventor
Joseph Frey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of EP2442649A1 publication Critical patent/EP2442649A1/en
Publication of EP2442649A4 publication Critical patent/EP2442649A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Definitions

  • the present invention relates to potentiators of glutamate receptors and their use in therapy. More specifically, the invention relates to the use of potentiators of glutamate receptors for reducing nicotine usage, reducing the urge to smoke or chew tobacco and inducing the cessation of smoking.
  • Glutamate is the primary excitatory neurotransmitter in the central nervous system and acts on two main classes of receptors, the ionotropic and metabotropic receptors.
  • Metabotropic glutamate receptors are G-protein- coupled receptors that modulate postsynaptic responses to glutamate and presynaptic release of glutamate, GABA and 5-HT. Eight subtypes of metabotropic glutamate receptors have been identified and classified into group I (mGluRI and mGluR ⁇ ), group Il (mGluR2 and mGluR3) and group III (mGluR4, mGluR6, mGluR7 and mG!uR8) receptors.
  • mGluR2 and mGluR3 are coupled via Gi/o to inhibition of adenylate cyclase and are involved primarily in the presynaptic inhibition of glutamate and GABA release.
  • mGlur2 receptors are expressed in discrete regions of the cerebral cortex, including the anterior cingulate and prefrontal orbital area; the limbic forebrain, including the amygdala and hippocampus; and to a lesser extent, the ventral tegmental area (VTA) and nucleus accumbens (NAc).
  • mGlurR3 is generally more diverse, and mGluR3 is also expressed in glia where it is thought play a role in modulating glutamate release as well as on GABAergic neurons.
  • mGlur2 receptors are positioned at extrasynaptic sites on neuronal terminals where they act as autoreceptors to suppress glutamate release under hyper- glutamatergic conditions.
  • Glutamate is thought to play a major role in mediating nicotine reward and relapse to smoking. Nicotine increases glutamate-mediated transmission throughout brain reward circuits. For example, nicotine activates excitatory nACh receptors on terminals of glutamatergic neurons projecting from brainstem (LDT/PPT) onto mesolimbic dopamine (DA) neurons in the VTA. DA neurons in turn project to the shell of the NAc.
  • LDT/PPT brainstem
  • DA mesolimbic dopamine
  • DA neurons in turn project to the shell of the NAc.
  • nicotine self- administration increases DA release in the shell of the NAc and nonselective mGlur2/3 receptor agonists have been shown to preferentially reduce DA release in the shell of the NAc, whereas mGlur2/3 blockade increased DA in the NAc shell.
  • Nonselective mGlur2/3 agonists also decrease nicotine self- administration, nicotine reward, and cue-induced reinstatement of nicotine seeking behavior
  • mGluR2 PAMs Positive allosteric modulators of mGlur2 (mGluR2 PAMs) act at a site remote from the glutamate-binding site on mGlur2 receptors and potentiate the activation of the glutamate-binding site. Such agents thus reduce the glutamate effect only under conditions of elevated extrasynaptic glutamate levels.
  • a mGlur2 PAM as described herein, will act in concert with endogenous glutamate to reduce dopamine release in the shell of the NAc and decrease nicotine self-administration, without significant aggravation of the brain reward deficits associated with nicotine withdrawal.
  • mGlur2 PAMs will act to dampen glutamate responses to nicotine, to reduce tobacco use, to reduce nicotine reward and cigarette consumption, and to lessen glutamate responses to smoking cues and smoking lapses without interfering with normal glutamatergic transmission or exacerbating nicotine withdrawal symptoms.
  • a method of reducing nicotine use or reducing nicotine withdrawal symptoms comprising: administering a therapeutically effective amount of a mGluR2 PAM to a subject in need thereof. More particularly a method is contemplated wherein the mGluR2 PAM is a compound selected from: 7-methyl-5-(3-piperazin-1-ylmethyl- [1 ,2,4]oxadiazol-5-yl)-2-(4-trifluoromethoxybenzyl)-2,3-dihydroisoindol-1-one; 2-(4-chloro-benzyl)-5-[3-(2,5-diaza-bicyclo[2.2.1]hept-2-ylmethyl)-
  • Still more particularly methods are contemplated using the compound described herein for reducing the smoking of tobacco, for reducing the chewing of tobacco and generally for reducing nicotine withdrawal symptoms experiences by subjects when attempting to reduce their dependence on tobacco.
  • compositions comprising a compound described herein and at least one pharmaceutically acceptable carrier or excipient for use in the methods described herein.
  • mGluR2 PAMs examples: mGlur2 PAMs and active metabolites, intermediates or derivatives thereof are contemplated to be useful for to dampen glutamate responses to nicotine, to reduce nicotine reward and cigarette consumption are described in Published International Patent applications WO2006020879, WO2007021309, WO2007095024, WO2007115077, WO2008100715 and WO2008130853, or United States Published Patent Applications US20070021606A1 , US20090069340A1 , US20070032469A1 , US20080227794A1 , US20070275966A1 , US20080125431 A1 , US20080306088A1 and US20080306077A1 , the entire contents of which are incorporated herein by reference.
  • any mGlur2 PAM described in any of the aforementioned patent applications will lessen glutamate responses to smoking cues and smoking lapses without interfering with normal glutamatergic transmission or exacerbating nicotine withdrawal symptoms, and will facilitate cessation of smoking, it is particularly contemplated that a compound selected from:
  • Efficacy of mGlur2 PAMs may be assessed by, for example, by a randomized, double-blind, double-dummy, placebo-controlled and active- controlled, parallel-group, human laboratory study conducted in healthy, treatment-seeking, male and female adult smokers. Other methods of assessing efficacy will be known to those of skill in the art. Efficacy may be shown by, for example, by abstinence from smoking, by an extended period before smoking recurrence or by subjective lessening of withdrawal symptoms and cravings (for example as assessed by the Minnesota Nicotine Withdrawal Scale - Revised and the QSU-Brief Questionnaire on smoking urges).
  • effects may be used to assess efficacy, for example, positive and negative affect as measured using the Positive and Negative Affect Schedule; Depressive symptoms as assessed using the Center for Epidemiologic
  • a therapeutically effective dose will depend on the subject being treated and that such a dose may in practice be determined by one skilled in the art, in general a dose from about 1 microgram to about 40 milligrams of a mGluR2 PAM as described herein is though to comprise a therapeutically effective dose.
  • a dose of from about 1 milligram to about 20 milligram of a mGluR2 PAM as described herein is though to comprise a therapeutically effective dose.
  • an appropriate dose regimen, the amount of each dose of a mGluR2 PAM administered, and the specific intervals between doses of each active agent will depend upon the subject being treated, the specific active agent being administered and the nature and severity of nicotine usage or condition being treated. More particularly it is contemplated that a dose of a mGluR2 PAM as described herein will be administered once per day.
  • Doses of mGluR2 PAMs will in general be administered in the form of compositions containing at least one pharmaceutically acceptable carrier or excipient.
  • compositions are intended to include the formulation of the mGluR2 PAM or a pharmaceutically acceptable salt with a pharmaceuticaliy acceptable carrier, and optionally other ingredients.
  • pharmaceutically acceptable carriers can be either solid or liquid.
  • compositions can be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions, suspensions, emulsions, creams, ointments, gels, nasal sprays, suppositories, finely divided powders or aerosols or nebulisers for inhalation, and for parenteral use (including intravenous, intramuscular or infusion) sterile aqueous or oily solutions or suspensions or sterile emulsions.
  • Liquid form compositions include solutions, suspensions, and emulsions.
  • Sterile water or water-propylene glycol solutions of the active compounds may be mentioned as an example of liquid preparations suitable for parenteral administration.
  • Liquid compositions can also be formulated in solution in aqueous polyethylene glycol solution.
  • Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavoring agents, stabilizers, and thickening agents as desired.
  • Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural synthetic gums, resins, methylcellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art.
  • Solid form compositions include powders, tablets, dispersible granules, capsules, cachets, and suppositories.
  • a solid carrier can be one or more substances that may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.
  • the carrier in powders, can be a finely divided solid, which is in a mixture with the finely divided active component.
  • the active component In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
  • a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient sized molds and allowed to cool and solidify.
  • Suitable carriers are magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like.
  • composition is also intended to include the formulation of the mGluR2 PAM active ingredient with encapsulating material as a carrier providing a capsule in which the active component (with or without other carriers) is surrounded by a carrier which is, thus, in association with it. Similarly, cachets are included.
  • the pharmaceutical compositions can be in unit dosage form.
  • the composition is divided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparations, for example, packeted tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of any of these packaged forms. Methods of preparing dosage forms are disclosed in, for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania, 15th Edition, 1975.
  • compositions may be formulated for any suitable route and means of administration.
  • Pharmaceutically acceptable carriers or diluents include those used in formulations suitable for oral, rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal, epidural, intraperitoneally, intrathoracically, intracerebroventricularly, and by injection into the joints) administration.
  • Formulations may conveniently be presented in unit dosage form and may be prepared by any method well known in the art of pharmacy.

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods of using potentiators of glutamate receptors for reducing nicotine usage, reducing the urge to smoke or chew tobacco or inducing the cessation of smoking are described.

Description

THE USE OF METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS FOR REDUCING NICOTINE DEPENDENCE - 772
Field of the Invention: The present invention relates to potentiators of glutamate receptors and their use in therapy. More specifically, the invention relates to the use of potentiators of glutamate receptors for reducing nicotine usage, reducing the urge to smoke or chew tobacco and inducing the cessation of smoking.
Background:
Glutamate is the primary excitatory neurotransmitter in the central nervous system and acts on two main classes of receptors, the ionotropic and metabotropic receptors. Metabotropic glutamate receptors are G-protein- coupled receptors that modulate postsynaptic responses to glutamate and presynaptic release of glutamate, GABA and 5-HT. Eight subtypes of metabotropic glutamate receptors have been identified and classified into group I (mGluRI and mGluRδ), group Il (mGluR2 and mGluR3) and group III (mGluR4, mGluR6, mGluR7 and mG!uR8) receptors.
Group Il mGluR (mGluR2 and mGluR3) are coupled via Gi/o to inhibition of adenylate cyclase and are involved primarily in the presynaptic inhibition of glutamate and GABA release. mGlur2 receptors are expressed in discrete regions of the cerebral cortex, including the anterior cingulate and prefrontal orbital area; the limbic forebrain, including the amygdala and hippocampus; and to a lesser extent, the ventral tegmental area (VTA) and nucleus accumbens (NAc). Expression of mGlurR3 is generally more diverse, and mGluR3 is also expressed in glia where it is thought play a role in modulating glutamate release as well as on GABAergic neurons. mGlur2 receptors are positioned at extrasynaptic sites on neuronal terminals where they act as autoreceptors to suppress glutamate release under hyper- glutamatergic conditions.
Glutamate is thought to play a major role in mediating nicotine reward and relapse to smoking. Nicotine increases glutamate-mediated transmission throughout brain reward circuits. For example, nicotine activates excitatory nACh receptors on terminals of glutamatergic neurons projecting from brainstem (LDT/PPT) onto mesolimbic dopamine (DA) neurons in the VTA. DA neurons in turn project to the shell of the NAc. In rats, nicotine self- administration increases DA release in the shell of the NAc and nonselective mGlur2/3 receptor agonists have been shown to preferentially reduce DA release in the shell of the NAc, whereas mGlur2/3 blockade increased DA in the NAc shell. Nonselective mGlur2/3 agonists also decrease nicotine self- administration, nicotine reward, and cue-induced reinstatement of nicotine seeking behavior (relapse) in rats without significant aggravation of the brain reward deficits associated with nicotine withdrawal.
Description of the Invention:
Positive allosteric modulators of mGlur2 (mGluR2 PAMs) act at a site remote from the glutamate-binding site on mGlur2 receptors and potentiate the activation of the glutamate-binding site. Such agents thus reduce the glutamate effect only under conditions of elevated extrasynaptic glutamate levels. Thus, we contemplate that a mGlur2 PAM, as described herein, will act in concert with endogenous glutamate to reduce dopamine release in the shell of the NAc and decrease nicotine self-administration, without significant aggravation of the brain reward deficits associated with nicotine withdrawal. It is further contemplated that in humans, mGlur2 PAMs will act to dampen glutamate responses to nicotine, to reduce tobacco use, to reduce nicotine reward and cigarette consumption, and to lessen glutamate responses to smoking cues and smoking lapses without interfering with normal glutamatergic transmission or exacerbating nicotine withdrawal symptoms.
Thus, a method of reducing nicotine use or reducing nicotine withdrawal symptoms is contemplated comprising: administering a therapeutically effective amount of a mGluR2 PAM to a subject in need thereof. More particularly a method is contemplated wherein the mGluR2 PAM is a compound selected from: 7-methyl-5-(3-piperazin-1-ylmethyl- [1 ,2,4]oxadiazol-5-yl)-2-(4-trifluoromethoxybenzyl)-2,3-dihydroisoindol-1-one; 2-(4-chloro-benzyl)-5-[3-(2,5-diaza-bicyclo[2.2.1]hept-2-ylmethyl)-
[1 ,2,4]oxadiazol-5-yl]-7-methyl-2,3-dihydro-isoindol-1-one;
2-(4-chloro-benzyl)-7-methyl-5-[3-(3-methyl-piperazin-1-ylmethyl)-
[1 ,2,4]oxadiazol-5-yl]-2,3-dihydro-isoindol-1-one; 2-(4-chloro-benzyl)-7-methyl-5-(3-piperazin-1-ylmethyl-[1 ,2,4]oxadiazol-5-yl)-
2,3-dihydro-isoindol-1 -one;
2-(4-chloro-benzyl)-7-methyl-5-[3-(2-methyl-piperazin-1-ylmethyl)-
[1 ,2,4]oxadiazol-5-yl]-2,3-dihydro-isoindol-1-one;
2-(4-chloro-benzyl)-7-methyl-5-[3-(2-methyl-piperazin-1-ylmethyl)- [1 ,2,4]oxadiazol-5-yl]-2,3-dihydro-isoindol-1-one;
7-chloro-5-(5-piperazin-1-ylmethyl-[1 ,2,4]oxadiazol-3-yl)-2-(4- trifluoromethoxybenzyl)-2,3-dihydroisoindol-1-one;
7-chloro-2-(4-chlorobenzyl)-5-(5-piperazin-1-ylmethyl-[1 ,2,4]oxadiazol-3-yl)-
2,3-dihydroisoindol-1 -one; 7-methyl-5-(5-piperazin-1 -ylmethyl-[1 ,2,4]oxadiazol-3-yl)-2-(4- trifluoromethoxybenzyl)-2,3-dihydroisoindol-1-one;
2-(4-chlorobenzyl)-7-methyl-5-(5-piperazin-1-ylmethyl-[1 ,2,4]oxadiazol-3-yl)-
2,3-dihydroisoindoI-1 -one;
5-[5-(2,5-diaza-bicyclo[2.2.1]hept-2-ylmethyl)-[1 ,2,4]oxadiazol-3-yl]-7-methyl- 2-(4-trifluoromethoxybenzyl)-2,3-dihydroisoindol-1-one;
2-[(S)-1 -(4-chloro-phenyl)-ethyl]-7-methyl-5-(5-piperazin-1-ylmethyl-
[1 ,2,4]oxadiazol-3-yl)-2,3-dihydro-isoindol-1-one;
2-[(S)-1-(4-chloro-phenyl)-ethyl]-5-{5-[(1S,4S)-1-(2,5-diaza-bicyclo[2.2.1]hept-
2-yl)methyl]-[1 ,2,4]oxadiazol-3-yl}-7-methyl-2,3-dihydro-isoindol-1-one; 2-(4-chloro-benzyl)-7-methyl-5-[5-(2-methyl-piperazin-1-ylmethyl)-
[1 ,2,4]oxadiazol-3-yl]-2,3-dihydroisoindol-1 -one;
2-(4-chloro-benzyl)-7-methyl-5-[5-(2-methyl-piperazin-1-ylmethyl)-
[1 ,2,4]oxadiazol-3-yi]-2,3-dihydroisoindol-1-one;
2-(4-chloro-benzyl)-7-methyl-5-[5-(3-methyl-piperazin-1-ylmethyl)- [1 ,2,4]oxadiazol-3-yl]-2,3-dihydroisoindol-1-one;
7-chloro-5-[5-(3,3-dimethyl-piperazin-1-ylmethyl)-[1 ,2,4]oxadiazol-3-yI]-2-(4- trifluoromethoxybenzyl)-2,3-dihydroisoindol-1-one; 7-methyl-5-[5-(1 -piperazin-1 -yl-ethyl)-[1 ,2,4]oxadiazol-3-yl]-2-(4- trifluoromethoxy-benzyl)-2,3-dihydro-isoindol-1-one;
2-(4-chloro-benzyl)-7-methyl-5-[5-(1 -piperazin-1 -yl-ethyl)-[1 , 2, 4]oxadiazol-3- yl]-2,3-dihydro-isoindol-1-one, or 2-[(S)-1 -(4-chloro-phenyl)-ethyl]-7-methyl-5-[5-(1 -piperazin-1 -yl-ethyl)-
[1 ,2,4]oxadiazol-3-yl]-2,3-dihydro-isoindol-1-one, or a pharmaceutically acceptable salt, active metabolite, intermediate or derivative, hydrate or solvate of any foregoing compound.
Still more particularly methods are contemplated using the compound described herein for reducing the smoking of tobacco, for reducing the chewing of tobacco and generally for reducing nicotine withdrawal symptoms experiences by subjects when attempting to reduce their dependence on tobacco.
Pharmaceutical compositions are contemplated comprising a compound described herein and at least one pharmaceutically acceptable carrier or excipient for use in the methods described herein.
It is also contemplated that compounds described herein or a pharmaceutically acceptable salts, active metabolites, intermediates or derivatives, hydrates or solvates of such compounds may be used as a medicament.
The use of compounds described herein or a pharmaceutically acceptable salts, active metabolites, intermediates or derivatives, hydrates or solvates of such compounds may be used in the manufacture of a medicament for the reduction of nicotine withdrawal symptoms, or the reduction of tobacco use.
Examples: mGluR2 PAMs: mGlur2 PAMs and active metabolites, intermediates or derivatives thereof are contemplated to be useful for to dampen glutamate responses to nicotine, to reduce nicotine reward and cigarette consumption are described in Published International Patent applications WO2006020879, WO2007021309, WO2007095024, WO2007115077, WO2008100715 and WO2008130853, or United States Published Patent Applications US20070021606A1 , US20090069340A1 , US20070032469A1 , US20080227794A1 , US20070275966A1 , US20080125431 A1 , US20080306088A1 and US20080306077A1 , the entire contents of which are incorporated herein by reference.
While it is contemplated that any mGlur2 PAM described in any of the aforementioned patent applications will lessen glutamate responses to smoking cues and smoking lapses without interfering with normal glutamatergic transmission or exacerbating nicotine withdrawal symptoms, and will facilitate cessation of smoking, it is particularly contemplated that a compound selected from:
7-methyl-5-(3-piperazin-1-ylmethyl-[1 ,2,4]oxadiazol-5-yl)-2-(4- trifluoromethoxybenzyl)-2,3-dihydroisoindol-1-one;
2-(4-chloro-benzyl)-5-[3-(2,5-diaza-bicyclo[2.2.1]hept-2-ylmethyl)- [1 ,2,4]oxadiazol-5-yl]-7-methyl-2,3-dihydro-isoindol-1-one;
2-(4-chloro-benzyl)-7-methyl-5-[3-(3-methyl-piperazin-1-ylmethyl)- [1 ,2,4]oxadiazol-5-yl]-2,3-dihydro-isoindol-1-one;
2-(4-chloro-benzyl)-7-methyl-5-(3-piperazin-1-ylmethyl- [1 ,2,4]oxadiazol-5-yl)-2,3-dihydro-isoindol-1-one; 2-(4-chloro-benzyl)-7-methyl-5-[3-(2-methyl-piperazin-1-ylmethyl)-
[1 ,2,4]oxadiazol-5-yl]-2,3-dihydro-isoindol-1-one,
2-(4-chloro-benzyl)-7-methyl-5-[3-(2-methyl-piperazin-1-ylmethyl)- [1 ,2,4]oxadiazol-5-yl]-2,3-dihydro-isoindol-1-one;
7-chloro-5-(5-piperazin-1-ylmethyl-[1 ,2,4]oxadiazol-3-yl)-2-(4- trifluoromethoxybenzyl)-2,3-dihydroisoindol-1-one;
7-chloro-2-(4-chlorobenzyl)-5-(5-piperazin-1-ylmethyl-[1 ,2,4]oxadiazol- 3-yl)-2,3-dihydroisoindol-1-one;
7-methyl-5-(5-piperazin-1-ylmethyl-[1 ,2,4]oxadiazol-3-yl)-2-(4- trifluoromethoxybenzyl)-2,3-dihydroisoindol-1-one; 2-(4-chlorobenzyl)-7-methyl-5-(5-piperazin-1-ylmethyl-[1 ,2,4]oxadiazol-
3-yl)-2,3-dihydroisoindol-1-one;
5-[5-(2,5-diaza-bicyclo[2.2.1 ]hept-2-ylmethyl)-[1 ,2,4]oxadiazol-3-yl]-7- methyl-2-(4-trifluoromethoxybenzyl)-2,3-dihydroisoindol-1 -one; 2-[(S)-1-(4-chloro-phenyl)-ethyl]-7-methyl-5-(5-piperazin-1-ylmethyl- [1 ,2,4]oxadiazol-3-yl)-2,3-dihydro-isoindol-1 -one;
2-[(S)-1-(4-chloro-phenyl)-ethyl]-5-{5-[(1S,4S)-1-(2,5-diaza- bicyclo^^.iJhept^-yOmethyll-ti ^^Joxadiazol-S-ylJ-y-methyl^.S-dihydro- isoindol-1-one;
2-(4-chloro-benzyl)-7-methyl-5-[5-(2-methyl-piperazin-1-ylmethyl)- [1 ,2,4]oxadiazol-3-yl]-2,3-dihydroisoindoI-1 -one;
2-(4-chloro-benzyl)-7-methyl-5-[5-(2-methyl-piperazin-1-ylmethyl)- [1 ,2,4]oxadiazol-3-yl]-2,3-dihydroisoindoI-1 -one; 2-(4-chloro-benzyl)-7-methyl-5-[5-(3-methyl-piperazin-1 -ylmethyl)-
[1 ,2,4]oxadiazol-3-yl]-2,3-dihydroisoindol-1 -one;
7-chloro-5-[5-(3,3-dimethyl-piperazin-1-ylmethyl)-[1 ,2,4]oxadiazol-3-yl]- 2-(4-trifluoromethoxybenzyl)-2,3-dihydroisoindol-1-one;
7-methyl-5-[5-(1 -piperazin-1 -yl-ethyl)-[1 ,2,4]oxadiazol-3-yl]-2-(4- trifluoromethoxy-benzyl)-2,3-dihydro-isoindol-1-one;
2-(4-chloro-benzyl)-7-methyl-5-[5-(1 -piperazin-1 -yl-ethyl)- [1 ,2,4]oxadiazol-3-yl]-2,3-dihydro-isoindol-1-one, or
2-[(S)"1-(4-chloro-phenyl)-ethyl]-7-methyl-5-[5-(1 -piperazin-1 -yl-ethyl)- [1 ,2,4]oxadiazol-3-yl]-2,3-dihydro-isoindol-1-one, or a pharmaceutically acceptable salt, active metabolite, intermediate, derivative, hydrate or solvate of any foregoing compound as described in US20080306088A1 or US20080306077A1 will have particular utility for this purpose. Efficacy: Efficacy of mGlur2 PAMs may be assessed by, for example, by a randomized, double-blind, double-dummy, placebo-controlled and active- controlled, parallel-group, human laboratory study conducted in healthy, treatment-seeking, male and female adult smokers. Other methods of assessing efficacy will be known to those of skill in the art. Efficacy may be shown by, for example, by abstinence from smoking, by an extended period before smoking recurrence or by subjective lessening of withdrawal symptoms and cravings (for example as assessed by the Minnesota Nicotine Withdrawal Scale - Revised and the QSU-Brief Questionnaire on smoking urges).
Other effects may be used to assess efficacy, for example, positive and negative affect as measured using the Positive and Negative Affect Schedule; Depressive symptoms as assessed using the Center for Epidemiologic
Studies - Depression scale; Anxiety levels as assessed using the Speilberger State-Trait Anxiety Inventory, or Cue reactivity utilizing: 1 ) A Visual Probe Task which assesses attentional bias toward salient cues, and; 2) a Cue Reactivity Task which measures subjective craving in response to in vivo smoking versus neutral stimuli. Effective doses:
While it is contemplated that a therapeutically effective dose will depend on the subject being treated and that such a dose may in practice be determined by one skilled in the art, in general a dose from about 1 microgram to about 40 milligrams of a mGluR2 PAM as described herein is though to comprise a therapeutically effective dose.
More particularly, a dose of from about 1 milligram to about 20 milligram of a mGluR2 PAM as described herein is though to comprise a therapeutically effective dose. In general, an appropriate dose regimen, the amount of each dose of a mGluR2 PAM administered, and the specific intervals between doses of each active agent will depend upon the subject being treated, the specific active agent being administered and the nature and severity of nicotine usage or condition being treated. More particularly it is contemplated that a dose of a mGluR2 PAM as described herein will be administered once per day. Doses of mGluR2 PAMs will in general be administered in the form of compositions containing at least one pharmaceutically acceptable carrier or excipient. Compositions:
Compositions are intended to include the formulation of the mGluR2 PAM or a pharmaceutically acceptable salt with a pharmaceuticaliy acceptable carrier, and optionally other ingredients. For preparing pharmaceutical compositions, inert, pharmaceutically acceptable carriers can be either solid or liquid. For example, compositions can be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions, suspensions, emulsions, creams, ointments, gels, nasal sprays, suppositories, finely divided powders or aerosols or nebulisers for inhalation, and for parenteral use (including intravenous, intramuscular or infusion) sterile aqueous or oily solutions or suspensions or sterile emulsions.
Liquid form compositions include solutions, suspensions, and emulsions. Sterile water or water-propylene glycol solutions of the active compounds may be mentioned as an example of liquid preparations suitable for parenteral administration. Liquid compositions can also be formulated in solution in aqueous polyethylene glycol solution. Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavoring agents, stabilizers, and thickening agents as desired. Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural synthetic gums, resins, methylcellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art.
Solid form compositions include powders, tablets, dispersible granules, capsules, cachets, and suppositories. A solid carrier can be one or more substances that may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.
In powders, the carrier can be a finely divided solid, which is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
For preparing suppository compositions, a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient sized molds and allowed to cool and solidify. Suitable carriers are magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like.
The term composition is also intended to include the formulation of the mGluR2 PAM active ingredient with encapsulating material as a carrier providing a capsule in which the active component (with or without other carriers) is surrounded by a carrier which is, thus, in association with it. Similarly, cachets are included.
The pharmaceutical compositions can be in unit dosage form. In such form, the composition is divided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparations, for example, packeted tablets, capsules, and powders in vials or ampoules. The unit dosage form can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of any of these packaged forms. Methods of preparing dosage forms are disclosed in, for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania, 15th Edition, 1975.
Compositions may be formulated for any suitable route and means of administration. Pharmaceutically acceptable carriers or diluents include those used in formulations suitable for oral, rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal, epidural, intraperitoneally, intrathoracically, intracerebroventricularly, and by injection into the joints) administration. Formulations may conveniently be presented in unit dosage form and may be prepared by any method well known in the art of pharmacy.

Claims

Claims:
1. A method of reducing nicotine use or reducing nicotine withdrawal symptoms comprising: administering a therapeutically effective amount of a mGluR2 PAM to a subject in need thereof.
2. A method according to claim 1 wherein said mGluR2 PAM is a compound selected from:
7~methyl-5-(3-piperazin-1 -ylmethyl-[1 ,2,4]oxadiazol-5-yl)-2-(4- trifluoromethoxybenzyl)-2,3-dihydroisoindol-1-one;
2-(4-chloro-benzyl)-5-[3-(2,5-diaza-bicyclo[2.2.1]hept-2-ylmethyl)- [1 ,2,4]oxadiazol-5-yl]-7-methyl-2,3-dihydro-isoindol-1-one;
2-(4-chloro-benzyl)-7-methyl-5-[3-(3-methyl-piperazin-1-ylmethyl)- [1 ,2,4]oxadiazol-5-yl]-2,3-dihydro-isoindol-1-one;
2-(4-chloro-benzyl)-7-methyl-5-(3-piperazin-1-ylmethyl-[1 ,2,4]oxadiazol-5-yl)- 2,3-dihydro-isoindol-1 -one;
2-(4-chloro-benzyl)-7-methyl-5-[3-(2-methyl-piperazin-1-ylmethyl)- [1 ,2,4]oxadiazol-5-yl]-2,3-dihydro-isoindol-1-one;
2-(4-chloro-benzyl)-7-methyl-5-[3-(2-methyl-piperazin-1-ylmethyl)- [1 ,2,4]oxadiazol-5-yl]-2,3-dihydro-isoindol-1-one;
7-chloro-5-(5-piperazin-1-ylmethyl-[1 ,2,4]oxadiazol-3-yl)-2-(4- trifluoromethoxybenzyl)-2,3-dihydroisoindol-1-one;
7-chloro-2-(4-chlorobenzyl)-5-(5-piperazin-1-ylmethyl-[1 ,2,4]oxadiazol-3-yl)- 2,3-dihydroisoindol-1 -one;
7-methyl-5-(5-piperazin-1-ylmethyl-[1 ,2,4]oxadiazol-3-yl)-2-(4- trifluoromethoxybenzyl)-2,3-dihydroisoindol-1-one;
2-(4-chlorobenzyl)-7-methyl-5-(5-piperazin-1-ylmethyl-[1 ,2,4]oxadiazol-3-yl)- 2,3-dihydroisoindol-1 -one; δ-tS^.δ-diaza-bicyclo^^.ilhept^-ylmethyO-ti ^^joxadiazol-S-yO^-methyl- 2-(4-trifluoromethoxybenzyl)-2,3-dihydroisoindol-1-one;
2-[(S)-1-(4-chloro-phenyl)-ethyl]-7-methyl-5-(5-piperazin-1-ylmethyl- [1 ,2,4]oxadiazol-3-yl)-2,3-dihydro-isoindol-1 -one; 2-[(S)-1-(4-chloro-phenyl)-ethyl]-5-{5-[(1 S,4S)-1-(2,5-diaza-bicyclo[2.2.1]hept- 2-yl)methyl]-[1 ,2,4]oxadiazol-3-yl}-7-methyl-2,3-dihydro-isoindol-1-one;
2-(4-chloro-benzyl)-7-methyl-5-[5-(2-methyl-piperazin-1-ylmethyl)- [1 ,2,4]oxadiazol-3-yl]-2,3-dihydroisoindol-1 -one;
2-(4-chloro-benzyl)-7-methyl-5-[5-(2-methyl-piperazin-1-ylmethyl)- [1 ,2,4]oxadiazol-3-yl]-2,3-dihydroisoindol-1-one;
2-(4-chloro-benzyl)-7-methyl-5-[5-(3-methyl-piperazin-1-ylmethyl)- [1 ,2,4]oxadiazol-3-yl]-2,3-dihydroisoindol-1-one;
7-chloro-5-[5-(3,3-dimethyl-piperazin-1-ylmethyl)-[1 ,2,4]oxadiazol-3-yl]-2-(4- trifluoromethoxybenzyl)-2,3-dihydroisoindol-1-one;
7-methyl-5-[5-(1-piperazin-1-yl-ethyl)-[1 ,2,4]oxadiazol-3-yl]-2-(4- trifiuoromethoxy-benzyl)-2,3-dihydro-isoindol-1-one;
2-(4-chloro-benzyl)-7-methyl-5-[5-(1-piperazin-1-yl-ethyl)-[1 ,2,4]oxadiazol-3- yl]-2,3-dihydro-isoindol-1 -one, or
2-[(S)-1-(4-chloro-phenyl)-ethyl]-7-methyl-5-[5-(1-piperazin-1-yl-ethyl)- [1 ,2,4]oxadiazol-3-yl]-2,3-dihydro-isoindol-1-one, or a pharmaceutically acceptable salt, hydrate or solvate of any foregoing compound.
3. A method according to claim 1 or 2, for reducing the smoking of tobacco.
4. A method according to claim 1 or 2, for reducing the chewing of tobacco.
5. A method for reducing nicotine withdrawal symptoms according to claim 1 or 2.
6. A pharmaceutical composition comprising a compound according to claim 2 and at least one pharmaceutically acceptable carrier or excipient.
7. A compound according to claim 2 for use as a medicament.
8. The use of a compound according to claim 2 in the manufacture of a medicament for the reduction of nicotine withdrawal symptoms, or the reduction of tobacco use.
EP10790110A 2009-06-19 2010-06-16 The use of metabotropic glutamate receptor potentiators for reducing nicotine dependence Withdrawn EP2442649A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21847809P 2009-06-19 2009-06-19
PCT/US2010/038802 WO2010148074A1 (en) 2009-06-19 2010-06-16 The use of metabotropic glutamate receptor potentiators for reducing nicotine dependence

Publications (2)

Publication Number Publication Date
EP2442649A1 true EP2442649A1 (en) 2012-04-25
EP2442649A4 EP2442649A4 (en) 2013-04-03

Family

ID=43356736

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10790110A Withdrawn EP2442649A4 (en) 2009-06-19 2010-06-16 The use of metabotropic glutamate receptor potentiators for reducing nicotine dependence

Country Status (4)

Country Link
EP (1) EP2442649A4 (en)
JP (1) JP2012530710A (en)
CN (1) CN102548407A (en)
WO (1) WO2010148074A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020102198A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
WO2020102150A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420719D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
TW200911255A (en) * 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
D.R. HELTON ET AL: "LY354740: a metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in rats", NEUROPHARMACOLOGY, vol. 36, no. 11-12, 1 November 1997 (1997-11-01), pages 1511-1516, XP055049732, ISSN: 0028-3908, DOI: 10.1016/S0028-3908(97)00170-6 *
IVÁN COLLADO ET AL: "(2 S ,1' S ,2' S ,3' R )-2-(2'-Carboxy-3'-methylcyclopropyl) Glycine Is a Potent and Selective Metabotropic Group 2 Receptor Agonist with Anxiolytic Properties", JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, no. 17, 1 August 2002 (2002-08-01), pages 3619-3629, XP055049936, ISSN: 0022-2623, DOI: 10.1021/jm0110486 *
LIECHTI MATTHIAS E ET AL: "Role of the glutamatergic system in nicotine dependence dependence - Implications for the discovery and development of new pharmacological smoking cessation therapies", CNS DRUGS, vol. 22, no. 9, 2008, pages 705-724, XP002690433, ISSN: 1172-7047 *
See also references of WO2010148074A1 *

Also Published As

Publication number Publication date
JP2012530710A (en) 2012-12-06
CN102548407A (en) 2012-07-04
EP2442649A4 (en) 2013-04-03
WO2010148074A1 (en) 2010-12-23

Similar Documents

Publication Publication Date Title
Freitas et al. In vivo pharmacological interactions between a type II positive allosteric modulator of α7 nicotinic ACh receptors and nicotinic agonists in a murine tonic pain model
RS59002B1 (en) Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells
US20090281078A1 (en) Combination of sabcomeline with a neuroleptic agent to treat psychotic disorders
AU2019233449B2 (en) Medicament for treating cough
US20040082543A1 (en) Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
KR20100054812A (en) Methods and compositions for treating schizophrenia using antipsychotic combination therapy
EP0279114B1 (en) Medicaments for the treatment or prevention of the withdrawal syndrome
EP1699488A2 (en) Therapeutic combination for cognition enhancement and psychotic disorders
EP3446565B1 (en) Methods for treating antipsychotic-induced weight gain
CA2644656A1 (en) Treatment of pain
JP2002308801A (en) Combination treatment for depression, obsessional disease and mental disease
JP2014196328A (en) COMBINATION MEDICINE OF NICOTINIC ACETYLCHOLINE α7 RECEPTOR AGONIST
MXPA02001198A (en) Combination treatment for depression.
AU2011215870A1 (en) Methods and compositions for improving cognitive function
MX2007011436A (en) Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions.
WO2010148074A1 (en) The use of metabotropic glutamate receptor potentiators for reducing nicotine dependence
US20090318414A1 (en) Mono and Combination Therapy with M1/M4 Muscarinic Agonist (Sabcomeline) for Treatment of Prodromal Syndrome
EP0345931B1 (en) Certain paf antagonist/antihistamine combinations and methods
CA2238815A1 (en) Composition for treating pain
JP5557409B2 (en) Combination of (S) -2- (benzylaminomethyl) -2,3,8,9-tetrahydro-7H-1,4-dioxino (2,3) Eindol-8-one with a neuroleptic
WO2010064047A1 (en) Use of sabcomeline for the treatment of add or adhd
KR20030010740A (en) Medicines for the Prevention and Treatment of Neurodegenerative Diseases
JPH10508027A (en) How to treat anxiety
HK1180543A (en) Methods for treating antipsychotic-induced weight gain

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120104

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/445 20060101ALI20130122BHEP

Ipc: A61K 31/44 20060101ALI20130122BHEP

Ipc: A01N 43/40 20060101AFI20130122BHEP

Ipc: A61P 25/34 20060101ALN20130122BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/44 20060101ALI20130219BHEP

Ipc: A01N 43/40 20060101AFI20130219BHEP

Ipc: A61K 31/445 20060101ALI20130219BHEP

Ipc: A61P 25/34 20060101ALN20130219BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20130228

17Q First examination report despatched

Effective date: 20130418

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130829